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Abstract
The majority of diseases causing sudden death or sudden onset of serious 
restriction of quality of life are thrombotic disease. Myocardial infarction is often 
caused by thrombotic occlusion of coronary arterial branches. Ischemic stroke is 
also caused by occlusion of cerebral arteries with thrombi. In patients admitted to 
the hospital and immobility, venous thromboembolism causing pulmonary embo-
lism is a major cause of death. The risk of cardiovascular events is influenced by 
food intake. Yet, the mechanism between specific food intake and the risk of throm-
botic disease is still to be elucidated. Recent progress of computer and information 
technology allows us to describe complex biological phenomena such as thrombosis 
from basic principles of physics and chemistry. Coupling blood flow, platelet, 
coagulation, and fibrinolysis allows us to understand the contributing role of each 
factor for thrombus formation. Yet, the precise role of food intake to influence the 
risk of thrombosis is still to be elucidated. Coupling basic research and large-scale 
clinical research will further clarify the role of various types of food intake in the 
risk of thrombosis.
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1. Introduction
Thrombosis is the leading cause of death in the world. Indeed, atherothrombosis 
including coronary artery diseases and cerebrovascular diseases is the top cause of 
death in various regions of the world [1]. Venous thrombosis including deep venous 
thrombosis and pulmonary embolism is the third cause of death in hospitalized 
patients [2]. Thrombosis is a disease caused by thrombi formed at various ves-
sels. The major symptom differs substantially depending upon the site where the 
thrombi developed. Typically, arterial thrombosis such as myocardial infarction 
and ischemic stroke is symptomatic even when the thrombi are small (e.g., less than 
1 mm in diameter) [3]. On the other hand, venous thrombosis is asymptomatic until 
thrombi become substantially large such as the ones that occlude several pulmonary 
arteries to cause pulmonary embolism [4]. In both arterial and venous thromboses, 
platelets are cells that contribute to initial thrombus formation. Coagulation and 
fibrinolysis are systems necessary to regulate the size of fibrin thrombi.
It is noteworthy that there is homogeneity in risk factors for various arte-
rial/venous thromboses despite wide variation of clinical manifestation [5]. 
Framingham study demonstrated that cigarette smoking, diabetes mellitus (DM), 
dyslipidemia, and hypertension are strong predictors for the future onset of arterial 
thrombosis represented by acute myocardial infarction [6]. Recent international 
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registries also confirm that these risk factors are contributing factors for the recur-
rence of cardiovascular events [7]. Moreover, international registries also suggested 
these parameters as risk factors of venous thrombosis [8]. These clinical observa-
tions suggested the presence of common pathways for the onset of arterial and 
venous thrombosis [9].
The Framingham registry suggested the contributory role of obesity and less 
exercise as the predictors for future prevalence of risk factors. These abnormali-
ties represented as visceral obesity-related syndrome is named as “metabolic 
syndrome.” In metabolic syndrome patients, insulin resistance is one of the major 
contributors [10]. Increased body weight, high blood pressure, and dyslipidemia 
are common manifestations of metabolic syndrome. Long-term exposure to a high-
calorie diet and lack of good exercise are supposed as underlining mechanisms 
for the onset of metabolic syndromes. The risk of thrombotic disease including 
arterial and venous thrombosis is speculated to be high in patients with metabolic 
syndrome.
2. Platelet adhesion at the site of endothelial injuries
Blood is flowing to maintain homeostasis inside the human body. Blood cells 
have specific functions: erythrocytes bring oxygen to tissues, leukocytes protect 
from infection, and platelets stop bleeding promptly. As shown in Figure 1, large 
and heavy erythrocytes tend to be located in the center of blood flow. Small cells 
of platelets circulate interacting with endothelial cells [11]. In the case where 
endothelial cells have a physiological function, platelets do not interact with 
them [12]. Platelets collide with the vessel wall and promptly go back to the 
blood flow without platelet activation. On the other hand, when endothelial cell 
function was disturbed by physical or chemical stimuli, endothelial cells lose 
their ability to keep antithrombotic function. Then, platelets immediately start 
the interaction with endothelial cells [12]. At the time, von Willebrand factor 
(VWF) is expressed on the cell surface of stimulated endothelial cells. Platelets 
capture VWF through glycoprotein (GP)Ibα. GPIbα is expressed on the surface 
Figure 1. 
Role of erythrocytes and blood flow in platelet adhesion at the site of endothelial injury. This figure 
demonstrates the three-dimensional distribution of erythrocytes, platelets, and endothelial cells. Erythrocytes 
accumulate in the center of blood flow by biorheological effects. Accordingly, platelets circulate close to 
endothelial cells. In the presence of normally functioning endothelial cells, platelets do not adhere nor are 
activated, but just return to blood flow (panel A). If the endothelial cell function was disturbed by various 
stimulations, platelets are adhered and activated through their interaction with von Willebrand factor (VWF).
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of platelet regardless if they are activated or not [13]. Thus, initial adhesion of 
platelets at the site of endothelial cell damage occurs predominantly as a physical 
phenomenon, which occurs immediately without time-consuming biological 
process. Historically, the vast majority of vessel damage is caused by trauma. 
Rapid accumulation of platelets at the site of endothelial injury plays an impor-
tant role to keep our blood in our vessel system for surviving.
The potential impact of erythrocytes for the onset and growth of thrombosis 
has first caught the interest of researchers in the 1960s [14]. Biorheological axial 
accumulation of flowing platelets was also recognized at the same time [15]. 
Clinical studies also support the notion that higher hematocrit values are related to 
higher risk of thrombotic diseases such as myocardial infarction [16]. These results 
strongly suggest the biophysical role of erythrocytes for thrombus formation. These 
rheological effects could hardly be controlled by food intake. In another aspect, 
erythrocytes also influence the function of platelet with biochemical modulation 
[17–19]. Indeed, erythrocytes are a huge source of ADP [20], which is one of the 
most potent platelet-stimulating agents [21, 22]. There is potential effects of food 
intake for influencing erythrocytes components which can influence thrombogenic-
ity of platelet [23, 24].
Recent advances in computer technology allowed us to predict the structure 
and function of VWF bound with GPIbα from the physical movement of atoms 
and water molecules [25, 26]. By the method, physical force generated by VWF 
binding with GPIbα could be predicted. Platelet adhesion at injured vessel wall is 
summarized in Figure 2. Platelets are cells with a diameter of approximately 5 μm. 
But, when platelet adhered at the site of vessel damage, only part of platelet bound 
with VWF. Molecular dynamic prediction revealed that single bond of VWF and 
GPIbα could generate binding force approximately 70 pN [25]. Fluid dynamic force 
applied to platelets reaches to a couple hundred pN when the cell receives detach-
ing force from arterial blood flow. Theoretically, several bonds between VWF and 
GPIbα are enough to stop platelets from adhering to the vessel wall. The mechanism 
of thrombus formation is a complicated process, but platelet adhesion under blood 
flow condition could now be constructed from physical movement of atoms and 
water molecules.
Figure 2. 
Platelet adhesion at the site of endothelial damage under blood flow conditions. Platelet adhesion is mediated 
exclusively by its glycoprotein (GP)Ibα binding with von Willebrand factor (VWF). Adhered platelets receive 
fluid dynamic force, but platelets continue to adhere until the detaching force becomes larger than the binding 
force generated between VWF and GPIbα.
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It is of particular importance that endothelial damage is not caused only by acute 
physical or chemical stimulation. In the recent era, human beings enjoy longer life 
than those who lived hundreds of years ago. Just like carrying human being, vessel 
system become old when people become old. Longer time exposure of vessel wall 
to atherogenic lipids such as LDL cholesterol and its related local biological reac-
tion causes atherosclerosis [27, 28]. Antithrombotic potential of endothelial cell in 
patients with atherosclerosis is reduced when compared to younger normal ones. 
Moreover, plaque rupture exposes subendothelial thrombotic materials to vessel 
lumen. Thus, atherothrombotic events occur frequently [29] in the era of aging 
society. The initial event resulting in symptomatic atherothrombosis is always 
platelet adhesion at the site of endothelial injury.
By understanding the mechanism of atherosclerosis and atherothrombosis, it 
is rather easy to understand that various types of food intake influence the risk 
of thrombosis. As regards nutritional factor, there is a hot discussion concerning 
cholesterol. Some suggested potential benefit of cholesterol restriction for preven-
tion of atherothrombosis. The other suggest there are no relationship between daily 
cholesterol  intake and the risk of atherothrombotic event risk.
3. Activation of coagulation cascade and fibrinolysis
Symptomatic atherothrombotic events such as acute myocardial infarction occur 
when organ perfusing arterial branch was occluded by thrombi. The diameter of 
organ perfusing vessels is substantially larger than a single cell of platelet. Indeed, 
the diameter of platelets is just 2–5 μm, while the diameter of myocardial perfusing 
coronary arterial branches is 2–3 mm. The size of vessel diameter is typically 1000 
more than the size of platelet diameter. It is nonrealistic to imagine that coronary 
arterial branches were occluded by platelet thrombi. Indeed, when coronary arte-
rial thrombi causing myocardial infarction are aspirated by thrombo-aspiration 
therapy, the main component of occlusive thrombi was fibrin (Figure 3). It is 
Figure 3. 
Major components of thrombi causing acute myocardial infarction. Sample thrombi were aspirated from 
patients with acute myocardial infarction. The main results and study protocols were published elsewhere [53]. 
Here, electron microscopy results are shown. Fibrin fibrils could be seen around activated platelets (arrow).
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noteworthy that fibrin fibrils are detected around activated platelets (Figure 3 is the 
product in collaboration with Prof. Yujiro Asada at Miyazaki University).
The lipid components of activated platelet changed from the ones at the quiescent 
state. Negatively charged phospholipids appeared on the surface of activated platelets 
[22]. Then, various coagulation factors accumulated around the lipid to form pro-
thrombin complex. On the activated platelet, thrombin generation occurs extremely 
efficiently. Indeed, thrombin generation rate in the absence of activated platelet and 
tissue factor is almost 0 as compared to that in its presence. At the site of atheroma 
rupture, large enough fibrin thrombi were formed as a result of the accumulation of 
activated platelet and exposure of tissue factor from the ruptured atheroma. Tissue 
factor accumulated in the atheroma is generated from inflammatory cells, which 
migrated into the atheroma. In the animal study, dietary lipid restriction reduces the 
amount of tissue factor accumulated in the atheroma [30]. The clinical factor of the 
reduction of the onset of myocardial infarction by the use of lipid-lowering therapy 
[31] may be related to reduction of lipid accumulation and subsequent reduction in 
tissue factor accumulated in the atheroma. Moreover, there are several publications 
indicating the impact of food intake for the lipid component of blood cells [23, 24]. 
The rate of fibrin formation at the site of endothelial damage and platelet accumula-
tion should be modified by food from both activated platelet-derived procoagulant 
activity and the amount of tissue factors accumulated in the atheroma.
The process of thrombus formation at the site of endothelial injury is com-
plex. We have attempted to develop the process model of thrombus formation as 
shown in Figure 4 [32]. The model is still simple but includes various physically 
and chemically different events. First, the model implemented the effect of blood 
flow, which is a purely physical phenomenon. Second, the model includes platelet 
Figure 4. 
Coupling model of blood flow, platelet, coagulation, and fibrinolysis. Thrombus formation at the site of 
endothelial injury is modeled. Nonactivated platelets (NP) adhered at the site of endothelial injury through 
von Willebrand factor (VWF) and collagen are exposed there. NP become activated platelets (AP) by 
their interaction with VWF/collagen (①). AP has a potential to convert prothrombin to thrombin on their 
membrane surface (②). After production of thrombin from prothrombin (③), thrombin converts soluble 
fibrinogen to fibrin thrombi. (④) thrombin also has a function to further activate platelets through thrombin 
receptor stimulation. (⑤) Fibrinolytic system is also incorporated in this model. Functional endothelial cells 
constitutively release both tissue-type plasminogen activator (t-PA: ⑥) and plasminogen activator inhibitor 
(PAI)-1 (⑦). T-PA converts plasminogen to plasmin, which has fibrinolytic activity (⑧) unless inactivated by 
binding with PAI-1. Plasmin is a strong enzyme able to degrade fibrin. Its function is immediately neutralized 
by its binding with a2-plasmin inhibitor to form plasmin a2-plasmin inhibitor complex (PIC: ⑨).
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adhesion and activation. Platelet adhesion is implemented to be medicated by its 
GPIbα binding with von Willebrand factor (VWF) (① in Figure 4). GPIbα bind-
ing with VWF is a chemical phenomenon, but the binding force is a physical one. 
We have implemented both in the same model. Platelets were implemented to be 
activated to change their biological roles (② in Figure 4). This process is a biological 
process. The detailed process model of platelet activation was published elsewhere 
[33]. Briefly, platelets were settled to be captured by VWF under blood flow condi-
tion. Collagen exposed at the site of endothelial injury also interacts with platelet 
and contributed to platelet activation through its receptor, namely, GPVI [34]. 
Then, activated platelet was settled to have stronger capacity to bind with injured 
vessel wall, cohesion each other, and possess the capacity to express coagulogenic 
phospholipids. Then, prothrombin conversion to thrombin was settled to occur only 
on the surface of activated platelets (③ in Figure 4). Thrombin function is neutral-
ized promptly by its interaction with antithrombin III. Thrombin implemented to 
have function to convert fibrinogen to fibrin (④ in Figure 4) and further activated 
platelet through thrombin receptor stimulations [35].
There are several coagulation factors, the function of which is regulated strongly 
by food intake. Gla-domain of coagulation factors plays crucial roles in the accumu-
lation of coagulation factors around exposed negatively charged phospholipids on 
activated platelets [36]. Gla-domain also plays crucial roles for enzymatic func-
tion of coagulation factors. Carboxylation of Gla-domain is mediated by vitamin 
K. Thus, coagulation cascade does not work well in the absence of vitamin K or 
in patients taking vitamin K inhibitor. It is noteworthy that there are many foods 
including fermented food that are known to contain abundant vitamin K. Strict 
food restriction is necessary to keep the anticoagulant effects of vitamin K inhibi-
tors. Recently, a larger load of vitamin K on health is cautioned [37].
The amount of fibrin formed at the site of endothelial injury was reduced by the 
effect of intrinsic fibrinolysis. Fibrinolysis is a complex pathway, but the details of 
which is simplified to be incorporated as shown in Figure 4. Vascular endothelial cells 
have balanced roles for fibrinolysis by releasing both fibrinolytic tissue-type plas-
minogen activator (t-PA: ⑥) and the one has antifibrinolytic effects of plasminogen 
activator inhibitor (PAI)-1 (⑦). Both of them are constitutively released from endo-
thelial cells. But the rates of their releases were individually controlled in individual 
endothelial cells. When the rate of t-PA release increases, the amount of fibrin formed 
around the endothelial cells becomes smaller. It becomes larger in the case when 
the rate of PAI-1 release increases. Free t-PA has a potential to convert plasminogen 
to plasmin. (⑧) Plasmin is a strong protease, which can dissolve many functional 
proteins including fibrinogen. To avoid too much protein degradation, activity of 
plasmin is promptly neutralized by the function of α2-plasmin inhibitor (α2-PI: ⑨).
Previous publication suggested increased PAI-1 release after acute myocardial 
infarction and its role for the increased recurrence of myocardial infarction [38]. 
Animal experiments revealed that the food coloring agent of crocin reduces activ-
ity of PAI-1 and prevents thrombosis [39]. In human, increased PAI-1 activity is 
reported at the time of too much intake of fat [40]. Total fibrinolytic activity in 
humans is also reported to be low in obese patients [41]. Decreased fibrinolytic 
activity in patients taking too much lipid is one potential reason of increased risk of 
thrombosis in these patients.
4. Role of various types of food intake for the risk of thrombosis
There are many reports suggesting the increase/decrease in the risk of throm-
bosis by various food and beverage intake. Framingham study suggested that coffee 
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consumption is related to lower risk of myocardial infarction [42]. However, the 
influence of coffee intake for the onset and recurrence of myocardial infarction is 
still under discussion because other reports suggested higher rate of sudden cardiac 
death in coffee intake in patients after myocardial infarction [43]. People have con-
sensus that food intake should influence the risk of arterial and venous thrombosis. 
The problem is that it is still hard to state which food reduces/increases the risk of 
thrombosis.
Old epidemiological studies suggested that the risk of myocardial infarction 
increased in Japanese people who immigrated to Hawaii or California than that of 
the ones staying in Japan. They have the same genetic background. Environmental 
factors including food should contribute to the change in the risk of population 
when moved to the US than staying in Japan. Lower cardiovascular death rate in 
Japan is still noted in the international registry of patients with atherothrombosis 
or non-valvular atrial fibrillation. Despite epidemiological data, it is still hard to 
identify what food specifically modulated the rate of thrombosis.
There are many specific diets that potentially influence thrombotic risk. Among 
them, sodium intake should be one of the most established factors to avoid car-
diovascular diseases. Low sodium intake clearly decreases the risk of heart failure 
[44], but its direct effects for thrombosis is still to be elucidated. Mediterranean 
diet is also related to lower risk of cardiovascular diseases [45]. But it is still difficult 
to identify the specific content of Mediterranean diet related to the reduction in 
the risk of CV disease. A plant-based diet seems beneficial in reducing the risk of 
cardiovascular disease, but it has both good qualities and bad qualities [46]. The 
relationship between food and the risk of cardiovascular diseases (mostly arterial 
thrombosis) is complex.
A recent publication suggested the positive correlation between red and pro-
cessed meat intake and risk of cardiovascular diseases. This study also suggested the 
negative relationship between the intake of yogurt, cheese, and eggs and CV disease 
risk [47]. The observation study is useful to find potential contributing factors but 
still includes many potential biases. Just like drug or medical intervention, random-
ized trials comparing a variety of food intake with hard endpoint of cardiovascular 
death, myocardial infarction, and ischemic stroke will give us more insight. 
However, in reality, it is hard to design such trials because people have the right 
to eat whatever they like. It is hard to make a restriction in food intake for a long 
period of time. The combination of observational study and the study to clarify the 
mechanism will give us the best available evidence now.
5. Metabolic syndrome and thrombosis: view from the mechanism
Metabolic syndrome is characterized as the presence of three apparent character-
istics including visceral obesity manifested as increasing waist circumference, dyslip-
idemia, hypertension, and high blood glucose. Underlining pathophysiology is insulin 
resistance and lipid accumulation. It is noteworthy that various cytokines (adipocyto-
kines) were identified from adipose tissue. Adiponectin is the one identified as factor 
reducing the risk of thrombosis by preventing endothelial dysfunction [48]. Indeed, 
decreased plasma concentration of adiponectin observed in obese patients may suggest 
the potential regulatory role of adiponectin for the onset of thrombotic diseases [49]. 
Despite difficulty in understanding the precise relationship among various cytokines 
and adiponectin [50], an apparent link between metabolic syndrome and decreased 
adiponectin is noteworthy. Various parameters for coagulation and fibrinolysis are also 
influenced in metabolic syndrome patients [51]. It is reasonable to recommend regular 
exercise to prevent metabolic syndrome and future onset of thrombosis [52].
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6. Conclusion
Obviously, food intake influences deeply the risk of thrombotic disease such as 
arterial and venous thrombotic diseases. Deeply reliable population-based clinical 
trials or nicely designed registry studies are awaited. Precise understand the mecha-
nism of thrombotic disease from hard science such as re-construction of biological 
phenomena from the physical movement of atoms.
Acknowledgements
Shinya Goto acknowledges financial support from MEXT/JSPS KAKENHI 
17 K19669, 18H01726, and 19H03661. SG acknowledges independent research grant 
support from Bristol-Myers Squibb (33999603). SG also acknowledges grant sup-
port from Vehicle Racing Commemorative Foundation and Nakatani Foundation 
for Advancement of Measuring Technologies in Biomedical Engineering. SG 
received research funding from Sanofi, Pfizer, and Ono.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
9Mechanism of Thrombus Formation in Regard to Diet
DOI: http://dx.doi.org/10.5772/intechopen.92382
References
[1] Leys D. Atherothrombosis: A 
major health burden. Cerebrovascular 
Diseases. 2001;11(Suppl 2):1-4
[2] Lindblad B, Sternby NH, 
Bergqvist D. Incidence of venous 
thromboembolism verified by necropsy 
over 30 years. British Medical Journal. 
1991;302:709-711
[3] Goto S. Propagation of arterial 
thrombi: Local and remote 
contributory factors. Arteriosclerosis, 
Thrombosis, and Vascular Biology. 
2004;24:2207-2208
[4] Moser KM, Fedullo PF, LitteJohn JK, 
Crawford R. Frequent asymptomatic 
pulmonary embolism in patients with 
deep venous thrombosis. Journal of 
the American Medical Association. 
1994;271:223-225
[5] Lowe GDO. Common risk factors for 
both arterial and venous thrombosis. 
British Journal of Haematology. 
2008;140:488-495
[6] Wilson PW. Established risk factors 
and coronary artery disease: The 
Framingham study. American Journal of 
Hypertension. 1994;7:7S-12S
[7] Bhatt DL, Eagle KA, Ohman EM, 
Hirsch AT, Goto S, Mahoney EM, 
et al. Comparative determinants of 
4-year cardiovascular event rates 
in stable outpatients at risk of or 
with atherothrombosis. Journal of 
the American Medical Association. 
2010;304:1350-1357
[8] Weitz JI, Haas S, Ageno W, 
Angchaisuksiri P, Bounameaux H, 
Nielsen JD, et al. Global anticoagulant 
registry in the field – venous 
thromboembolism (GARFIELD-
VTE). Thrombosis and Haemostasis. 
2016;116:1172-1179
[9] Mackman N. New insights into the 
mechanisms of venous thrombosis. 
The Journal of Clinical Investigation. 
2012;122:2331-2336
[10] McKeown NM, Meigs JB, 
Liu S, Saltzman E, Wilson PW, 
Jacques PF. Carbohydrate nutrition, 
insulin resistance, and the prevalence 
of the metabolic syndrome in the 
Framingham offspring cohort. Diabetes 
Care. 2004;27:538-546
[11] Goto S, Hasebe T, Takagi S. Platelets: 
Small in size but essential in the 
regulation of vascular homeostasis -  
translation from basic science to 
clinical medicine. Circulation Journal. 
2015;79:1871-1881
[12] Kawamura Y, Takahari Y, Tamura N, 
Eguchi Y, Urano T, Ishida H, et al. 
Imaging of structural changes in 
endothelial cells and thrombus 
formation at the site of FeCl(3)-
induced injuries in mice cremasteric 
arteries. Journal of Atherosclerosis and 
Thrombosis. 2009;16:807-814
[13] Goto S, Ikeda Y, Saldivar E, 
Ruggeri ZM. Distinct mechanisms of 
platelet aggregation as a consequence 
of different shearing flow conditions. 
The Journal of Clinical Investigation. 
1998;101:479-486
[14] Hellem AJ, Borchgrevink CF, 
Ames SB. The role of red cells in 
haemostasis: The relation between 
haematocrit, bleeding time and 
platelet adhesiveness. British Journal of 
Haematology. 1961;7:42-50
[15] Repetti RV, Leonard EF. Axial 
accumulation of red cells: Probable 
causes and effects of interest in artificial 
organs. Transactions - American 
Society for Artificial Internal Organs. 
1964;10:311-315
[16] Sorlie PD, Garcia-Palmieri MR, 
Costas R Jr, Havlik RJ. Hematocrit and 
risk of coronary heart disease: The 
New Insights into Metabolic Syndrome
10
Puerto Rico health program. American 
Heart Journal. 1981;101:456-461
[17] Santos MT, Valles J, Marcus AJ, 
Safier LB, Broekman MJ, Islam N, et al. 
Enhancement of platelet reactivity and 
modulation of eicosanoid production 
by intact erythrocytes. A new approach 
to platelet activation and recruitment. 
The Journal of Clinical Investigation. 
1991;87:571-580
[18] Valles J, Santos MT, Aznar J, 
Marcus AJ, Martinez-Sales V, Portoles M, 
et al. Erythrocytes metabolically enhance 
collagen-induced platelet responsiveness 
via increased thromboxane production, 
adenosine diphosphate release, and 
recruitment. Blood. 1991;78:154-162
[19] Rocca B, FitzGerald GA. Simply 
read: Erythrocytes modulate platelet 
function. Should we rethink the way we 
give aspirin? Circulation. 1997;95:11-13
[20] Bakhtiari N, Hosseinkhani S, 
Larijani B, Mohajeri-Tehrani MR, 
Fallah A. Red blood cell ATP/ADP & 
nitric oxide: The best vasodilators in 
diabetic patients. Journal of Diabetes 
and Metabolic Disorders. 2012;11:9
[21] Cattaneo M, Gachet C. ADP 
receptors and clinical bleeding 
disorders. Arteriosclerosis, Thrombosis, 
and Vascular Biology. 1999;19:2281-2285
[22] Goto S, Tamura N, Eto K, Ikeda Y, 
Handa S. Functional significance of 
adenosine 5′-diphosphate receptor 
(P2Y(12)) in platelet activation 
initiated by binding of von Willebrand 
factor to platelet GP Ibalpha induced 
by conditions of high shear rate. 
Circulation. 2002;105:2531-2536
[23] Vidgren HM, Agren JJ, Schwab U,  
Rissanen T, Hanninen O, Uusitupa MI. 
Incorporation of n-3 fatty acids into 
plasma lipid fractions, and erythrocyte 
membranes and platelets during dietary 
supplementation with fish, fish oil, 
and docosahexaenoic acid-rich oil 
among healthy young men. Lipids. 
1997;32:697-705
[24] Murphy KJ, Meyer BJ, Mori TA, 
Burke V, Mansour J, Patch CS, et al. 
Impact of foods enriched with n-3 
long-chain polyunsaturated fatty 
acids on erythrocyte n-3 levels and 
cardiovascular risk factors. The British 
Journal of Nutrition. 2007;97:749-757
[25] Shiozaki S, Takagi S, Goto S. 
Prediction of molecular interaction 
between platelet glycoprotein Ibalpha 
and von Willebrand factor using 
molecular dynamics simulations. 
Journal of Atherosclerosis and 
Thrombosis. 2016;23:455-464
[26] Goto S, Oka H, Ayabe K,  
Yabushita H, Nakayama M, 
Hasebe T, et al. Prediction of binding 
characteristics between von Willebrand 
factor and platelet glycoprotein Ibalpha 
with various mutations by molecular 
dynamic simulation. Thrombosis 
Research. 2019;184:129-135
[27] Libby P. Atherosclerosis: The 
new view. Scientific American. 
2002;286:46-55
[28] Hansson GK. Inflammation, 
atherosclerosis, and coronary artery 
disease. The New England Journal of 
Medicine. 2005;352:1685-1695
[29] Ruggeri ZM. Platelets in 
atherothrombosis. Nature Medicine. 
2002;8:1227-1234
[30] Aikawa M, Voglic SJ, Sugiyama S, 
Rabkin E, Taubman MB, Fallon JT, et al. 
Dietary lipid lowering reduces tissue 
factor expression in rabbit atheroma. 
Circulation. 1999;100:1215-1222
[31] Brown WV. The benefit 
of aggressive lipid lowering. 
Atherosclerosis. Supplements. 
2000;1:15-19
11
Mechanism of Thrombus Formation in Regard to Diet
DOI: http://dx.doi.org/10.5772/intechopen.92382
[32] Ayabe K, Goto S, Oka H, 
Yabushita H, Nakayama M, Tomita A, 
et al. Potential different impact of 
inhibition of thrombin function and 
thrombin generation rate for the growth 
of thrombi formed at site of endothelial 
injury under blood flow condition. 
Thrombosis Research. 2019;179:121-127
[33] Tomita A, Tamura N, Nanazawa Y, 
Shiozaki S, Goto S. Development of 
virtual platelets implementing 
the functions of three platelet 
membrane proteins with different 
adhesive characteristics. Journal of 
Atherosclerosis and Thrombosis. 
2015;22:201-210
[34] Goto S, Tamura N, Handa S, Arai M, 
Kodama K, Takayama H. Involvement 
of glycoprotein VI in platelet 
thrombus formation on both collagen 
and von Willebrand factor surfaces 
under flow conditions. Circulation. 
2002;106:266-272
[35] Angiolillo DJ, Capodanno D, 
Goto S. Platelet thrombin receptor 
antagonism and atherothrombosis. 
European Heart Journal. 2010;31:17-28
[36] Huang M, Rigby AC, Morelli X, 
Grant MA, Huang G, Furie B, et al. 
Structural basis of membrane binding 
by Gla domains of vitamin K-dependent 
proteins. Nature Structural Biology. 
2003;10:751-756
[37] Vermeer C. Vitamin K: The effect 
on health beyond coagulation - an 
overview. Food & Nutrition Research. 
2012;56:5329. DOI: 10.3402/fnr.
v56i0.5329
[38] Collet JP, Montalescot G, Vicaut E, 
Ankri A, Walylo F, Lesty C, et al. Acute 
release of plasminogen activator 
inhibitor-1 in ST-segment elevation 
myocardial infarction predicts mortality. 
Circulation. 2003;108:391-394
[39] Tsantarliotou MP, Lavrentiadou SN, 
Psalla DA, Margaritis IE, Kritsepi MG, 
Zervos IA, et al. Suppression of 
plasminogen activator inhibitor-1 
(PAI-1) activity by crocin ameliorates 
lipopolysaccharide-induced thrombosis 
in rats. Food and Chemical Toxicology. 
2019;125:190-197
[40] Byrne CD, Wareham NJ, 
Martensz ND, Humphries SE, Metcalfe JC, 
Grainger DJ. Increased PAI activity and 
PAI-1 antigen occurring with an oral fat 
load: Associations with PAI-1 genotype 
and plasma active TGF-beta levels. 
Atherosclerosis. 1998;140:45-53
[41] Basurto L, Sanchez L, Diaz A, 
Valle M, Robledo A, Martinez- 
Murillo C. Differences between 
metabolically healthy and unhealthy 
obesity in PAI-1 level: Fibrinolysis, 
body size phenotypes and metabolism. 
Thrombosis Research. 2019;180:110-114
[42] Noh HM, Park YS, Kim JH. Coffee 
consumption and coronary heart 
disease risk using the Framingham risk 
score. Asia Pacific Journal of Clinical 
Nutrition. 2017;26:931-938
[43] de Vreede-Swagemakers JJ, 
Gorgels AP, Weijenberg MP, 
Dubois-Arbouw WI, Golombeck B, 
van Ree JW, et al. Risk indicators for 
out-of-hospital cardiac arrest in patients 
with coronary artery disease. Journal of 
Clinical Epidemiology. 1999;52:601-607
[44] Kalogeropoulos A, Papadimitriou L, 
Georgiopoulou VV, Dunbar SB, 
Skopicki H, Butler J. Low- versus 
moderate-sodium diet in patients with 
recent hospitalization for heart failure: 
The PROHIBIT (prevent adverse 
outcomes in heart failure by limiting 
sodium) pilot study. Circulation. Heart 
Failure. 2020;13:e006389
[45] Lim CC, Hayes RB, Ahn J, 
Shao Y, Silverman DT, Jones RR, et al. 
Mediterranean diet and the 
association between air pollution and 
cardiovascular disease mortality risk. 
Circulation. 2019;139:1766-1775
New Insights into Metabolic Syndrome
12
[46] Baden MY, Liu G, Satija A, Li Y,  
Sun Q , Fung TT, et al. Changes in 
plant-based diet quality and Total and 
cause-specific mortality. Circulation. 
2019;140:979-991
[47] Key TJ, Appleby PN, Bradbury KE,  
Sweeting M, Wood A, Johansson I, 
et al. Consumption of meat, fish, 
dairy products, and eggs and risk of 
ischemic heart disease. Circulation. 
2019;139:2835-2845
[48] Ekmekci H, Ekmekci OB. The 
role of adiponectin in atherosclerosis 
and thrombosis. Clinical and 
Applied Thrombosis/Hemostasis. 
2006;12:163-168
[49] Matsuzawa Y, Funahashi T, 
Kihara S, Shimomura I. Adiponectin 
and metabolic syndrome. 
Arteriosclerosis, Thrombosis, and 
Vascular Biology. 2004;24:29-33
[50] Matsushita K, Yatsuya H, 
Tamakoshi K, Wada K, Otsuka R, 
Takefuji S, et al. Comparison 
of circulating adiponectin and 
proinflammatory markers regarding 
their association with metabolic 
syndrome in Japanese men. 
Arteriosclerosis, Thrombosis, and 
Vascular Biology. 2006;26:871-876
[51] Alessi M-C, Juhan-Vague I. 
Metabolic syndrome, haemostasis 
and thrombosis. Thrombosis and 
Haemostasis. 2008;99:995-1000
[52] Katzmarzyk PT, Leon AS, 
Wilmore JH, Skinner JS, Rao DC, 
Rankinen T, et al. Targeting the 
metabolic syndrome with exercise: 
Evidence from the HERITAGE family 
study. Medicine and Science in Sports 
and Exercise. 2003;35:1703-1709
[53] Hoshiba Y, Hatakeyama K, Tanabe T, 
Asada Y, Goto S. Co-localization of 
von Willebrand factor with platelet 
thrombi, tissue factor and platelets 
with fibrin, and consistent presence of 
inflammatory cells in coronary thrombi 
obtained by an aspiration device 
from patients with acute myocardial 
infarction. Journal of Thrombosis and 
Haemostasis. 2006;4:114-120
